Paragon Biosciences

5 items

April 29, 2026

Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy
Ecopipam, Emalex’s investigational asset for pediatric Tourette syndrome (TS), is a first‑in‑class selective dopamine D1 receptor [...]
February 23, 2021

Paragon Biosciences Appoints Jordan Dubow as Chief Medical Officer
Chicago, February 23, 2021—With continued growth [...]
February 2, 2021

Paragon Biosciences Launches CiRC Biosciences to Expand Cell and Gene Therapy Platform
Its vision restoration technology featured in Nature [...]
September 9, 2020

Jon DeVries Named Qlarity Imaging Chief Executive Officer
Chicago, September 9, 2020 – Life science innovator [...]
August 21, 2020

Harmony Biosciences Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
PLYMOUTH MEETING, PA and CHICAGO, IL, August 21, [...]